Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Calcium pyrophosphate deposition disease

Rheumatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Acute CPP arthritis can mimic sepsis

A hot swollen knee or wrist with fever and very high inflammatory markers may be calcium-pyrophosphate arthritis, septic arthritis or both; crowned dens syndrome can also resemble meningitis or giant cell arteritis.

Action: Use the urgent hot-joint or acute-neck-pain pathway, aspirate and culture before antibiotics when safe, obtain blood cultures in systemic illness, provide sepsis treatment without delay and avoid intra-articular corticosteroid until infection is reasonably excluded.

Synopsis

Recognise acute, chronic and asymptomatic calcium-pyrophosphate phenotypes, confirm crystals while excluding infection, identify important metabolic associations and treat inflammation without promising a crystal-dissolving therapy.

  • CPPD is an umbrella for asymptomatic chondrocalcinosis, acute CPP crystal arthritis, chronic CPP inflammatory arthritis and osteoarthritis with CPP deposits; avoid the imprecise term pseudogout when a phenotype can be named.
  • Acute CPP arthritis commonly affects an older adult's knee or wrist, can be intensely painful and febrile and may take longer than gout to settle.
  • The reference confirmation is CPP crystals in symptomatic-joint fluid: usually rhomboid or rod-shaped and weakly positively birefringent under compensated polarised light.
  • A negative crystal search does not fully exclude CPPD because crystals can be sparse and weakly birefringent; expert microscopy and prompt analysis improve yield.
  • Always send synovial culture when infection is possible. Chondrocalcinosis and CPP crystals can coexist with septic arthritis.
  • Plain radiography can show linear or punctate calcification in menisci, triangular fibrocartilage, symphysis or hyaline cartilage; absence of chondrocalcinosis does not exclude symptomatic disease.
  • Ultrasound is useful for accessible cartilage and effusion, while CT is the preferred test for crowned dens syndrome around the odontoid.

Key red flags

Fever, shock, prosthesis, recent joint procedure, skin breach or bacteraemia requires immediate septic-arthritis assessment regardless of chondrocalcinosis.

Acute severe neck pain with rigidity, fever, headache, focal neurology or altered consciousness requires urgent exclusion of meningitis, haemorrhage, spinal infection and giant cell arteritis.

A painful swollen hip, shoulder or other deep joint needs urgent image-guided aspiration because examination cannot reliably separate crystal disease from infection.

Trauma, anticoagulation or inability to bear weight widens the differential to fracture, haemarthrosis and structural injury before anti-inflammatory treatment.

Acute kidney injury, ulcer bleeding, heart failure or anticoagulation can make NSAID treatment dangerous; pregnancy changes colchicine and imaging decisions.

CPPD beginning before age 60, widespread deposits or strong family history should prompt a metabolic and inherited-cause assessment rather than an age-only explanation.

Crowned dens syndrome

Acute upper-neck pain, restricted rotation, fever and high inflammatory markers with peri-odontoid CT calcification defines this CPPD presentation.

Investigation priorities

01
Reference synovial-fluid crystal analysisFirst step

Confirm CPP crystals in a symptomatic joint and distinguish gout.

Management branches

First diagnostic priorityAspirate the hot joint

An acute effusion with severe warmth and restricted movement is present.

  1. Check sepsis, prosthesis, recent procedure, skin breach and bacteraemia and obtain observations and blood cultures when systemically unwell.
  2. Aspirate before antibiotics when safe, sending cell count, Gram stain, culture and expert polarised microscopy for CPP and urate crystals.
  3. Treat suspected infection immediately and remember that a positive CPP crystal result does not cancel microbiological risk.
Preferred local treatmentAspirate then inject

One accessible joint is affected and infection has been reasonably excluded.

  1. Remove as much inflammatory fluid as practical, document the specimen and use strict asepsis for any subsequent injection.
  2. Give joint-size-appropriate intra-articular corticosteroid, local cool treatment and short relative rest with post-injection infection warnings.
  3. Restore range and progressive loading as pain settles and reassess promptly if fever, swelling or pain worsens.

Key medicines

Intra-articular triamcinolone acetonideAfter aspiration and infection exclusion, inject 5 to 10 mg into a small joint or up to 40 mg into a large joint using the 40 mg/mL suspension and strict asepsis; dose depends on joint size and inflammation.CPPD is not a named licensed indication, although the product is licensed for inflammatory joint disorders. Never inject through infection or into a possibly septic or unstable joint. Warn about glucose rise, post-injection flare and infection and do not use fixed repeat intervals. Pregnancy requires an individual benefit-risk review.
Colchicine for acute CPP arthritisA common specialist off-label regimen is 500 micrograms orally twice daily for 3 to 5 days, reduced to once daily in selected older or renally impaired patients and stopped promptly when symptoms settle or toxicity occurs.This indication is off-label. Check eGFR, liver disease and macrolide, azole, ciclosporin, verapamil and statin interactions. Stop for diarrhoea or vomiting; accumulation can cause marrow failure, neuromyopathy and multiorgan toxicity. Pregnancy requires specialist benefit-risk review.
Open full textbook →Answer 2 questions
Sources and review status8 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • EULAR CPPD diagnosis recommendationsTerminology, synovial-fluid confirmation, imaging and metabolic associations.
  • EULAR CPPD management recommendationsAcute aspiration and injection, systemic treatment, prophylaxis and chronic disease options.
  • 2023 ACR and EULAR CPPD classification criteriaValidated symptomatic phenotypes, sufficient criteria and associated metabolic disorders.
  • EULAR imaging recommendations for crystal arthropathiesCurrent radiography, ultrasound and CT roles in CPPD.
  • Kenalog intra-articular UK product informationJoint-size dose, asepsis, infection and tendon restrictions.
  • Colchicine 500 microgram UK product informationOrgan, interaction, neuromuscular and reproductive safety relevant to off-label CPPD use.
  • Naproxen 250 mg UK product informationNSAID dosing, contraindications, interactions and pregnancy restrictions relevant to off-label CPPD use.
  • Prednisolone 5 mg UK product informationSteroid infection, metabolic, adrenal and reproductive safety relevant to off-label CPPD use.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·

Content changes
Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom